Manager, Clinical Biomarker Assays, Translational Science - Neuroscience

Benefits

Additional Information

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations. On August 8 th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant. In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024. #TeamArvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company's values and mission - to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform. We're really excited about the work we're doing inside and outside of Arvinas, and think you will be, too. But don't just take our word for it - learn more about life at Arvinas and what employees have to say . For more information, please visit www.arvinas.com . Position Summary We are seeking a highly motivated Manager, Clinical Biomarker Assays, Translational Science, Neuroscience with biomarker expertise to lead and execute clinical biomarker assay development, validation and implementation activities to support our neuroscience clinical programs. This individual will perform as the Clinical Biomarker Assay Lead within Translational Science to support Neuroscience programs, and will be responsible for clinical biomarker CROs evaluation and oversight, clinical biomarker assay development and validation, clinical sample testing execution, and high-quality biomarker data generation and transfer to support assessment of pharmacodynamics including target engagement, patient stratification, and disease progression. The successful candidate will combine strong scientific rigor with cross-functional leadership and a track record of overseeing development of biomarker assays for utilization in clinical studies. This position reports to Director, Translational Science - Neuroscience and can be located at our headquarters in New Haven, CT or work remotely from a location within the U.S. Principal Responsibilities Key responsibilities of this role include, but are not limited to: Conduct scientific and operational due diligence and selection of external biomarker CROs and assay platforms, leading vendor due diligence processes including, but not limited to assessment of biomarker technology, evaluations of biomarker assay feasibility, analytical performance and validation characteristics, and overall technical capability. Lead and oversee development, qualification, and validation of clinical biomarker assays (e.g., ELISA, Simoa, MSD, LC-MS/MS, Olink/SomaScan, NGS etc) in collaboration with internal teams and CROs, including review of assay analytical validation plans, biomarker reports, and technical documentation to ensure timely clinical biomarker assay deliverables and biomarker assay performance meets regulatory and industry standards for clinical use (e.g., GCLP, CLIA, CAP as applicable). Oversee external CROs/labs performing clinical biomarker testing, including vendor management. assay transfer and clinical sample testing. Ensure high-quality biomarker data generation, QC, and timely data transfer Cross-functional collaboration with Translational Science Lead, Clinical Operati

Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at arvinas? Share your experience